SlideShare ist ein Scribd-Unternehmen logo
1 von 51
Downloaden Sie, um offline zu lesen
DIAGNOSIS MANAGEMENT AND
RECENT ADVANCES IN CML
DR RAJESH S
PLAN
 Introduction
 BCR ABL and its Action
 Clinical and Laboratory Features
 Goals and Concepts of Management
 Diagnostic modalities
 Tyrosine Kinase Inhibitors
 Other Modalities of treatment
 Monitoring Of therapy
Chronic Myelogenous Leukemia
 CML is a MPD characterized by increased granulocytic
cell line, associated with erythroid and platelet
hyperplasia.
 The diagnosis of CML is established by identifying a
clonal expansion of a hematopoietic stem cell
possessing a reciprocal translocation between
chromosomes 9 and 22.
THE BCR-ABL MUTATION
 This translocation results in the head-to-tail fusion of the
breakpoint cluster region (BCR) gene on chromosome
22q11 with the ABL1 (named after the abelson murine
leukemia virus) gene located on chromosome 9q34.
The Ph Chromosome: t(9;22)
22
bcr
abl
Ph ( or 22q-)
bcr-abl
FUSION PROTEIN
WITH TYROSINE
KINASE ACTIVITY
9 9 q+
Head to tail fusion of BCR to ABL occurs following
9:22 translocation
This region is transcribed into BCR-ABL mRNA
BCR-ABL protein is produced(p210)
This protein Dimerises and becomes active tyrosine kinase
Many intracellular kinases are phosphorylated(eg c-myc,shc)
Cell proliferates,evades apoptosis
CML - DIAGNOSIS,MANAGEMENT AND RECENT ADVANCES
Erythrocytes
BCR ABL
MUTATION
OCCURS in
MYELOID
STEM CELLS
ALL COMPONENTS OF
MYELOID SERIES i.e
MYELOCYTES,RBC’S AND
PLATELETS ARE AFFECTED
CLINICAL AND LAB FEATURES
CLINICAL FEATURES
 30% patients are Asymptomatic at diagnosis.
 Symptoms are usually Non specific(Fatigue,anorexia,weight loss)
 Symptoms because of splenomegaly are common(abdominal pain,
dragging sensation in abdomen)
 Rare presentations include Vasoocclusive disease, cerebrovascular
accidents, myocardial infarction, venous thrombosis, priapism, visual
disturbances, and pulmonary insufficiency.
LABORATORY FEATURES
 Elevated white blood cell counts (WBCs), with increases in both immature
and mature granulocytes, are present at diagnosis. Usually <5% circulating
blasts and <10% blasts and promyelocytes are noted, with the majority of
cells being myelocytes, metamyelocytes, and band forms.
 Platelet counts are almost always elevated at diagnosis,
 Mild degree of normocytic normochromic anemia is present.
 Leukocyte alkaline phosphatase is low in CML cells.
LABORATORY FEATURES
 The marrow is hypercellular (granulocytic hyperplasia)
 Reticulin fibrosis
 Hyperuricemia and hyperuricosuria
 Serum vitamin B12-binding proteins are increased.
 Pseudohyperkalemia, and spurious hypoxemia and hypoglycemia.
CML - DIAGNOSIS,MANAGEMENT AND RECENT ADVANCES
ACCELERATED PHASE
(WHO DEFINITION)
 Blasts 10-19% in peripheral blood and or bone marrow.
 Peripheral Basophilia ≥20% in peripheral blood.
 Persistent thrombocytopenia(<100 x109 )
 Persistent thrombocytosis(>1000 x109 )
 Increasing spleen size and white blood count despite therapy.
 Cytogenetic evidence of clonal evolution
10-19%
BLASTIC PHASE
(WHO DEFINITION)
 Blasts >20% in peripheral blood and or bone marrow.
 Extramedullary blast proliferation
 Large cluster of Blasts in bone marrow Biopsy.
>20%
Clinical progression of CML
Chronic phase
Median 5–6
years
stabilization
Accelerated
phase
Median duration
6–9 months
Blast crisis
Median survival
3–6 months
Advanced phases
ACQUISITION OF
NEW
MUTATIONS LIKE
TRISOMY 8, P53
MUTATION.
BLAST CRISIS IS
CONVERSION OF
CML INTO AML
This acquisition of new
mutations is called as
CYTOGENIC CLONAL
EVOLUTION
GOALS, CONCEPTS OF MANAGEMENT
AND DIAGNOSTIC MODALITIES
Response to treatment can be defined under three sequential
categories.
1.Hematological Response
2.Cyto-Genetic Response(CyR)
3.Molecular Response(MR)
Definitions of Responses to Treatments
Hematologic Response
Complete Hematologic response
1) Normal PB counts (WBC < 10 and plt < 450)
2) Normal WBC differential
3) No Dz symptoms
4) Normalization of the size of the liver and spleen
Cytogenetic Responses: Ph+ Metaphases
1) complete: 0%
2) partial: 1% - 35%
3) minor: 36% - 65%
4) minimal: 66% - 95%
5) none: 96% - 100%
Molecular Responses: ratio of Bcr-Abl/Abl
Major Molecular Response
3-log10 reduction from initial diagnosis sample
(i.e. 25 →0.025)
Amount of Dz
1X1012
1X1011
1X1010
1X10 8-9
CURE???
Head to tail fusion of BCR to ABL occurs following
9:22 translocation
This region is transcribed into BCR-ABL mRNA
BCR-ABL protein is produced(p210)
This protein Dimerises and becomes active tyrosine kinase
Intracellular kinases are phosphorylated(eg c-myc,shc)
Cell proliferates,evades apoptosis
Hematological Response is
measure by normalization of
leukocytes and platelet count
and decrease in spleen size
Various Guidelines suggest that Complete
hematological response should be obtained
within 3 months of initiating therapy
Complete hematologic response
 Complete normalization of PB counts, leukocyte count < 10 x 109/L
 Platelet count < 450 x 109/L
 No myelocytes, promyelocytes, or blasts in PB
 No palpable splenomegaly
 No disease symptoms
DONE BY : CBC
Head to tail fusion of BCR to ABL occurs following
9:22 translocation
This region is transcribed into BCR-ABL mRNA
BCR-ABL protein is produced(p210)
This protein Dimerises and becomes active tyrosine kinase
I Intracellular kinases are phosphorylated(eg c-myc,shc)
Cell proliferates,evades apoptosis
Cyto-genetic response is
measured by quantifying 9:22
transolocation.
This can be done by
1.Karyotyping/conventional cytogenetics
2.FISH
CYTO-GENETIC STUDIES
 Requires a bone marrow aspirate for optimal
metaphases.
 In bone marrow sample, dividing cells are
halted at interphase with the help of
colchicine and then trypsin and giemsa stains
are added in order for G-BANDING of
chromosomes.
 Allows for evaluation of 9:22
translocation, Clonal evolution as well as
additional chromosomal abnormalities in the
non-Ph+ clones.
 Atleast 20 interphases are examined before
reporting.
FLOURESCENT IN-SITU HYBRIDISATION
Cytogenetic response
 Complete : No Ph+ metaphases
 Partial : 1% to 35% Ph+ metaphases
 Minor : > 35% Ph+ metaphases
 Major : 0% to 35% Ph+ metaphases (complete + partial)
Done By: Cyto-genetics/Fish
Head to tail fusion of BCR to ABL occurs following
9:22 translocation
This region is transcribed into BCR-ABL mRNA
BCR-ABL protein is produced(p210)
This protein Dimerises and becomes active tyrosine kinase
Intracellular kinases are phosphorylated(eg c-myc,shc)
Cell proliferates,evades apoptosis
Molecular response is measured by
quantifying the Bcr-Abl mRNA
transcripts.
This can be done by
1.QPCR
Bcr-Abl
Bcr
Abl
cDNA
QUANTITATIVE PCR FOR BCR-ABL INTERPRETATION
0 3 6 9 12 15 18 21 24 27 30 33 36
PCR Cycle Number
Amount of
Fluorescence
High Concentration
Moderate
Concentration
Low Concentration
Molecular Response
 Major Molecular Response(MMR) : ≥ 3 log reduction in BCR-ABL mRNA or
BCR-ABL/ABL ≤ 0.1% by QRT-PCR (International Scale)
 Complete Molecular Response (CMR) : No detectable BCR-ABL mRNA
using assay with sensitivity at least 4.5 logs below standardized baseline
Done By: QPCR
PROGNOSTIC CLASSIFICATION
SOKAL INDEX
 Age
 Blast percentage
 Cytogenic clonal Evolution
 Spleen size
 Platelet counts
HASFORD INDEX
 Age
 Blast percentage
 Basophil and Eosinophils %
 Spleen size
 Platelet counts
TREATMENT WITH TYROSINE KINASE
INHIBITORS
CML - DIAGNOSIS,MANAGEMENT AND RECENT ADVANCES
CML - DIAGNOSIS,MANAGEMENT AND RECENT ADVANCES
IMATINIB
 Imatinib mesylate (Gleevec) functions through competitive inhibition at
the ATP-binding site of the Abl kinase in the inactive conformation,
which leads to inhibition of tyrosine phosphorylation of proteins involved
in Bcr-Abl signal transduction.
 It shows specificity for Bcr-Abl, the receptor for platelet-derived growth
factor, and Kit TK.
 Imatinib induces apoptosis in cells expressing Bcr-Abl.
FAQ ON IMATINIB
 What is the dose of imatinib?
400mg / day (maximum dose upto 800 mg can be given)
 What is the duration of treatment?
At present, treatment should be given for life. Trials in which the drug is
stopped after 2 years of achieving CMR has shown promising results.
 What are the adverse effects?
Myelo-suppression is the most common hematologic side effect. Others
are fluid retention, nausea, muscle cramps, diarrhea, and skin rashes.
 How to treat myelo-suppression following imatinib therapy?
withholding the drug until counts improves. Growth factors like GM-CSF
(filgrastim) can be used.
FAQ ON IMATINIB
 Can we use imatinib in pregnant patients?
imatinib is shown to be teratogenic and embryotoxic in animal studies.so it
is avoided in pregnancy
 Does imatinib affects fertility?
It has shown to cause oligospermia. So men desiring conception shold
consider sperm cryo-preservation before TKI therapy
 When to review the patient for monitoring response?
After 3 months of therapy and every 3 months thereafter.
CML - DIAGNOSIS,MANAGEMENT AND RECENT ADVANCES
MONITORING RESPONSE
 Patients on imatinib should be reviewed at 3rd month and investigations
to be done at that time are
1.CBC
2.Bone Marrow Cytogenetics/Blood FISH
3.QPCR
 If patient had achieved hematological and complete cytological
response, then patient can be monitored with QPCR every 3 months
thereafter until MMR is aceived, then QPCR can be done every 6 months.
 What is the ideal response at 3 months?
FAILURE CAN BE BECAUSE OF
1.Resistance to TKI
2.Cytogenic clonal evolution(i.e additional
mutations)
3.CML could be Ph negative type
4.Patient adherence problems(missing more
than 2 doses in a month)
Resistance to imatinib
Four mechanisms of resistance to imatinib have been described to date.
These are
1. Gene amplification i.e more Bcr-Abl are produced
 Treated by increasing dose to 800mg
2. Enhanced expression of multidrug exporter proteins
 Treated by increasing dose to 800mg
3. Mutations at the kinase site
 Replace with Nilotinib or Dasatinib
4. Alternative signaling pathways functionally compensating for the
imatinib - sensitive mechanisms (SRC family of kinases get mutated
and they start phosphorylating the kinases)
 Replace with Dasatinib
KINASE SITE MUTATIONS
 Mutations at the kinase domain occur in approximately half of
imatinib-resistant chronic-phase cases and even more frequently in
the more advanced phases of the disease.
 These mutations are being targeted by novel TK inhibitors that have a
different conformation than imatinib, demonstrating activity against
most imatinib-resistant mutations.
 Nilotinib, like imatinib, binds to the kinase domain in the inactive
conformation. Dasatinib binds to the kinase domain in the open
conformation and also inhibits the SRC (sarcoma) family of
kinases, addressing the last mechanism of resistance.
 CML with the T315I mutation is resistant to imatinib, nilotinib, and
dasatinib
Bcr-Abl imatinib
Mut. Bcr-Abl imatinib
Mut. Bcr-Abl dasatinib
NILOTINIB
 400 mg twice daily
 Associated with sudden death
 Causes QT prolongation
DASATINIB
 100 mg once daily
 Causes pleural effusions in 22% of
patients.
 Causes pulmonary arterial
hypertension
Both these drugs are now approved also as first line TKI’s for newly diagnosed
CML patients by the FDA due to their enhanced Cytogenetic and molecular
remissions within short time period
NEWER Drugs
 Omacetaxine (formerly known as homoharringtonine) Protein
translation inhibitor
 Sorafenib : Raf kinase inhibitor that down regulates down stream Bcr-
Abl targets
 FTY720 (also known as fingolimod) : Activation of protein
phosphatase 2A that is essential for ABL1-mediated leukemogenesis
Allogenic Hematopoietic Stem Cell Transplant(HSCT)
INDICATIONS IN CP-CML:
1.Patients with T315I Mutations
2.Bcr-Abl mutations that are resistant to all TKI’s
3.Patient intolerant to TKI’s
 Allogenic HSCT is no longer recommended as first line therapy in chronic
phase CML. It can be offered to candidates of accelerated or blast crisis.
 Even after HSCT TKI’s should be continued till one year.
CHEMOTHERAPY
 Currently reserved for rapid lowering of WBCs, reduction of
symptoms, and reversal of symptomatic splenomegaly.
 Hydroxyurea induces rapid disease control. The initial dose is 1–4
g/d; the dose should be halved with each 50% reduction of the
leukocyte count. Unfortunately, cytogenetic remissions with
hydroxyurea are uncommon.
 Busulphan, an alkylating agent that acts on early progenitor cells,
has a more prolonged effect. However not used because of its
serious side effects, which include unexpected, and occasionally
fatal, myelosuppression in 5–10% of patients; pulmonary,
endocardial, and marrow fibrosis; and an Addison-like wasting
syndrome
OTHER MODALITIES
 Intensive leukapheresis may control the blood counts in chronic-
phase CML; however, it is expensive and cumbersome. It may also
have a role in the treatment of pregnant women, in whom it is
important to avoid potentially teratogenic drugs.
 Splenectomy was used in CML in the past because of the suggestion
that evolution to the acute phase might occur in the spleen.
However, this does not appear to be the case, and splenectomy is
now reserved for symptomatic relief of painful splenomegaly
unresponsive to imatinib or chemotherapy, or for significant anemia
or thrombocytopenia associated with hypersplenism
HOW CAN WE MANAGE CML
PATIENTS IN MBGH HOSPITAL SETUP
Patients present
to us with
symptoms and
spleenomegaly
Patient is
suspected of Cml
in Peripheral
blood film
Confirm BCR-ABL
with FISH or
KARYOTYPING
Start on IMATINIB
therapy
FISH for Bcr-Abl costs Rs.4750
at SRL Religare Diagnostics(4-
7 days)
Imatinib starts from Rs.30 per
tablet
Karyotyping costs Rs.3100 at
Amolak Labs and report is
available after one month
NAME SALT MANUFACTURER COST/DAY PER MONTH
1.RESIMAT IMATINIB RESONANCE LABS RS.30.10 903
2.LUPITIB IMATINIB LUPIN RS.170 5100
3.MITINAB IM.MESYLATE GLENMARK RS.180 5400
4.MESYLONIB IM.MESYLATE MIRACALUS RS.300 9000
5.IMATIB IM.MESYLATE CIPLA RS.300 9000
6.CHEMOTINIB IM.MESYLATE NEON RS.300 9000
7.CELONIB IMATINIB CELON RS.320 9600
8.VEENAT IMATINIB NATCO RS.352 10560
THANK YOU

Weitere ähnliche Inhalte

Was ist angesagt?

Application of FISH in hematologic malignancies
Application of FISH in hematologic malignanciesApplication of FISH in hematologic malignancies
Application of FISH in hematologic malignanciesspa718
 
Chronic myeloid leukemia
Chronic myeloid leukemiaChronic myeloid leukemia
Chronic myeloid leukemiakhursheed falak
 
Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia (CLL)Subhash Thakur
 
The 5th edition of the World Health Organization Classification of Haematolym...
The 5th edition of the World Health Organization Classification of Haematolym...The 5th edition of the World Health Organization Classification of Haematolym...
The 5th edition of the World Health Organization Classification of Haematolym...Dr Seena Tresa Samuel
 
Acute lymphoblastic leukemia approach and treatment
Acute lymphoblastic leukemia approach and treatmentAcute lymphoblastic leukemia approach and treatment
Acute lymphoblastic leukemia approach and treatmentahmed mjali
 
Multiple myeloma
Multiple myelomaMultiple myeloma
Multiple myelomaBSMMU
 
Chronic Myelogenous Leukemia
Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia
Chronic Myelogenous LeukemiaAneesh Bhandary
 
Recent updates in Myeloproliferative Neoplasms
Recent updates in Myeloproliferative NeoplasmsRecent updates in Myeloproliferative Neoplasms
Recent updates in Myeloproliferative NeoplasmsDr. Niladri Sarkar
 
Acute leukemias aml-csbrp
Acute leukemias aml-csbrpAcute leukemias aml-csbrp
Acute leukemias aml-csbrpPrasad CSBR
 
Hairy cell leukmia
Hairy cell leukmiaHairy cell leukmia
Hairy cell leukmiaAhmed Allam
 
Cml presentation
Cml presentationCml presentation
Cml presentationmadurai
 
Acute myeloid leukemia
Acute myeloid leukemiaAcute myeloid leukemia
Acute myeloid leukemianamrathrs87
 
Acute lymphoblastic leukemia (ALL) dr arun haldia
Acute lymphoblastic leukemia (ALL)  dr arun haldiaAcute lymphoblastic leukemia (ALL)  dr arun haldia
Acute lymphoblastic leukemia (ALL) dr arun haldiaDr Arun Haldia
 
Lab Diagnosis of Chronic lymphoproliferative disorders (CLPD); Flowcytometric...
Lab Diagnosis of Chronic lymphoproliferative disorders (CLPD);Flowcytometric...Lab Diagnosis of Chronic lymphoproliferative disorders (CLPD);Flowcytometric...
Lab Diagnosis of Chronic lymphoproliferative disorders (CLPD); Flowcytometric...Dr Siddartha
 

Was ist angesagt? (20)

Chronic myeloid Leukemia
Chronic myeloid LeukemiaChronic myeloid Leukemia
Chronic myeloid Leukemia
 
Application of FISH in hematologic malignancies
Application of FISH in hematologic malignanciesApplication of FISH in hematologic malignancies
Application of FISH in hematologic malignancies
 
Minimal residual disease
Minimal residual diseaseMinimal residual disease
Minimal residual disease
 
Chronic myeloid leukemia
Chronic myeloid leukemiaChronic myeloid leukemia
Chronic myeloid leukemia
 
Chronic Myloid Leukemia overview (CML)
Chronic Myloid Leukemia overview (CML)Chronic Myloid Leukemia overview (CML)
Chronic Myloid Leukemia overview (CML)
 
Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia (CLL)
 
The 5th edition of the World Health Organization Classification of Haematolym...
The 5th edition of the World Health Organization Classification of Haematolym...The 5th edition of the World Health Organization Classification of Haematolym...
The 5th edition of the World Health Organization Classification of Haematolym...
 
L8 cml
L8 cmlL8 cml
L8 cml
 
Cml shiaom final
Cml shiaom finalCml shiaom final
Cml shiaom final
 
Cml ppt new 1
Cml ppt new 1Cml ppt new 1
Cml ppt new 1
 
Acute lymphoblastic leukemia approach and treatment
Acute lymphoblastic leukemia approach and treatmentAcute lymphoblastic leukemia approach and treatment
Acute lymphoblastic leukemia approach and treatment
 
Multiple myeloma
Multiple myelomaMultiple myeloma
Multiple myeloma
 
Chronic Myelogenous Leukemia
Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia
Chronic Myelogenous Leukemia
 
Recent updates in Myeloproliferative Neoplasms
Recent updates in Myeloproliferative NeoplasmsRecent updates in Myeloproliferative Neoplasms
Recent updates in Myeloproliferative Neoplasms
 
Acute leukemias aml-csbrp
Acute leukemias aml-csbrpAcute leukemias aml-csbrp
Acute leukemias aml-csbrp
 
Hairy cell leukmia
Hairy cell leukmiaHairy cell leukmia
Hairy cell leukmia
 
Cml presentation
Cml presentationCml presentation
Cml presentation
 
Acute myeloid leukemia
Acute myeloid leukemiaAcute myeloid leukemia
Acute myeloid leukemia
 
Acute lymphoblastic leukemia (ALL) dr arun haldia
Acute lymphoblastic leukemia (ALL)  dr arun haldiaAcute lymphoblastic leukemia (ALL)  dr arun haldia
Acute lymphoblastic leukemia (ALL) dr arun haldia
 
Lab Diagnosis of Chronic lymphoproliferative disorders (CLPD); Flowcytometric...
Lab Diagnosis of Chronic lymphoproliferative disorders (CLPD);Flowcytometric...Lab Diagnosis of Chronic lymphoproliferative disorders (CLPD);Flowcytometric...
Lab Diagnosis of Chronic lymphoproliferative disorders (CLPD); Flowcytometric...
 

Andere mochten auch (20)

Cml
CmlCml
Cml
 
chronic myeloid leukemia
chronic myeloid leukemiachronic myeloid leukemia
chronic myeloid leukemia
 
Cml
CmlCml
Cml
 
Recent advances in antithrombotics
Recent advances in antithromboticsRecent advances in antithrombotics
Recent advances in antithrombotics
 
Chronic leukemias
Chronic leukemiasChronic leukemias
Chronic leukemias
 
Recruit(1)
Recruit(1)Recruit(1)
Recruit(1)
 
Gastro Intestinal Stromal Tumours
Gastro Intestinal Stromal TumoursGastro Intestinal Stromal Tumours
Gastro Intestinal Stromal Tumours
 
Mood disorders
Mood disordersMood disorders
Mood disorders
 
Evaluation of Drugs used in CCF
Evaluation of Drugs used in CCFEvaluation of Drugs used in CCF
Evaluation of Drugs used in CCF
 
Pharmacotherapy of ibd
Pharmacotherapy of ibdPharmacotherapy of ibd
Pharmacotherapy of ibd
 
Gleevec group presentation#1
Gleevec group presentation#1Gleevec group presentation#1
Gleevec group presentation#1
 
Mydriatics
MydriaticsMydriatics
Mydriatics
 
Egfr in colorectal
Egfr in colorectalEgfr in colorectal
Egfr in colorectal
 
AN INNOVATIVE APPROACH TOWARDS THE TREATMENT of HEPATITIS C
AN INNOVATIVE APPROACH TOWARDS THE TREATMENT of HEPATITIS CAN INNOVATIVE APPROACH TOWARDS THE TREATMENT of HEPATITIS C
AN INNOVATIVE APPROACH TOWARDS THE TREATMENT of HEPATITIS C
 
Advance Non-Small Cell Lung Cancer final
Advance Non-Small Cell Lung Cancer finalAdvance Non-Small Cell Lung Cancer final
Advance Non-Small Cell Lung Cancer final
 
Hodgkin lymphoma presentation
Hodgkin lymphoma presentation Hodgkin lymphoma presentation
Hodgkin lymphoma presentation
 
FLT3 INHIBITORS
FLT3 INHIBITORSFLT3 INHIBITORS
FLT3 INHIBITORS
 
IMATINIB RESISTANT CML
IMATINIB RESISTANT CMLIMATINIB RESISTANT CML
IMATINIB RESISTANT CML
 
Important sites for pediatrician
Important sites for pediatricianImportant sites for pediatrician
Important sites for pediatrician
 
Recent advances in hplc and gc
Recent advances in hplc and gcRecent advances in hplc and gc
Recent advances in hplc and gc
 

Ähnlich wie CML - DIAGNOSIS,MANAGEMENT AND RECENT ADVANCES

Chronic myeloid leukemia
Chronic myeloid leukemiaChronic myeloid leukemia
Chronic myeloid leukemiadr k r sharma
 
Minimal Residual Disease in leukaemia andhematological malignancies
Minimal Residual Disease in leukaemia andhematological malignanciesMinimal Residual Disease in leukaemia andhematological malignancies
Minimal Residual Disease in leukaemia andhematological malignanciessadiya97
 
chronic leukemia.pptx
chronic leukemia.pptxchronic leukemia.pptx
chronic leukemia.pptxNatanA7
 
Chronic Myeloid Leukemia - notes 2022
Chronic Myeloid Leukemia - notes 2022Chronic Myeloid Leukemia - notes 2022
Chronic Myeloid Leukemia - notes 2022Best Doctors
 
Chronic myeloid leukemia
Chronic myeloid leukemiaChronic myeloid leukemia
Chronic myeloid leukemiaEram K.
 
Integrated haematopathology
Integrated haematopathology Integrated haematopathology
Integrated haematopathology Dr. Rajesh Bendre
 
CML دكتو.عبدالرزاق الاغبري.pdf
CML دكتو.عبدالرزاق الاغبري.pdfCML دكتو.عبدالرزاق الاغبري.pdf
CML دكتو.عبدالرزاق الاغبري.pdfnedalalazzwy
 
Chronic myeloid leukemia genetics гбйт ягш
Chronic myeloid leukemia genetics гбйт ягшChronic myeloid leukemia genetics гбйт ягш
Chronic myeloid leukemia genetics гбйт ягшssuser10ca4c
 
Myeloproliferative disorders
Myeloproliferative disordersMyeloproliferative disorders
Myeloproliferative disordersdrsapnaharsha
 
Chronic myeloid leukaemia
Chronic myeloid leukaemiaChronic myeloid leukaemia
Chronic myeloid leukaemiajackson711
 
Chronic Myeloid Leukemia(CML)
Chronic Myeloid Leukemia(CML)Chronic Myeloid Leukemia(CML)
Chronic Myeloid Leukemia(CML)Md. Al-Amin
 
Chronic leukemia
Chronic leukemiaChronic leukemia
Chronic leukemiaAnkita Sain
 

Ähnlich wie CML - DIAGNOSIS,MANAGEMENT AND RECENT ADVANCES (20)

Chronic myeloid leukemia
Chronic myeloid leukemiaChronic myeloid leukemia
Chronic myeloid leukemia
 
MPN AJIT SURYA SINGH
MPN AJIT SURYA SINGHMPN AJIT SURYA SINGH
MPN AJIT SURYA SINGH
 
Case presentation
Case presentationCase presentation
Case presentation
 
Minimal Residual Disease in leukaemia andhematological malignancies
Minimal Residual Disease in leukaemia andhematological malignanciesMinimal Residual Disease in leukaemia andhematological malignancies
Minimal Residual Disease in leukaemia andhematological malignancies
 
chronic leukemia.pptx
chronic leukemia.pptxchronic leukemia.pptx
chronic leukemia.pptx
 
Chronic leukemia
  Chronic leukemia    Chronic leukemia
Chronic leukemia
 
Chronic Myeloid Leukemia - notes 2022
Chronic Myeloid Leukemia - notes 2022Chronic Myeloid Leukemia - notes 2022
Chronic Myeloid Leukemia - notes 2022
 
Leucemia Mieloide Cronica
Leucemia Mieloide CronicaLeucemia Mieloide Cronica
Leucemia Mieloide Cronica
 
Chronic myeloid leukemia
Chronic myeloid leukemiaChronic myeloid leukemia
Chronic myeloid leukemia
 
Integrated haematopathology
Integrated haematopathology Integrated haematopathology
Integrated haematopathology
 
CML دكتو.عبدالرزاق الاغبري.pdf
CML دكتو.عبدالرزاق الاغبري.pdfCML دكتو.عبدالرزاق الاغبري.pdf
CML دكتو.عبدالرزاق الاغبري.pdf
 
CML Chronic Myeloid Leukemia.pdf
CML Chronic Myeloid Leukemia.pdfCML Chronic Myeloid Leukemia.pdf
CML Chronic Myeloid Leukemia.pdf
 
Chronic myeloid leukemia genetics гбйт ягш
Chronic myeloid leukemia genetics гбйт ягшChronic myeloid leukemia genetics гбйт ягш
Chronic myeloid leukemia genetics гбйт ягш
 
Myeloproliferative disorders
Myeloproliferative disordersMyeloproliferative disorders
Myeloproliferative disorders
 
CML
CMLCML
CML
 
Chronic myeloid leukaemia
Chronic myeloid leukaemiaChronic myeloid leukaemia
Chronic myeloid leukaemia
 
CHRONIC MYELOID LEUKEMIA
CHRONIC MYELOID LEUKEMIACHRONIC MYELOID LEUKEMIA
CHRONIC MYELOID LEUKEMIA
 
Chronic Myeloid Leukemia(CML)
Chronic Myeloid Leukemia(CML)Chronic Myeloid Leukemia(CML)
Chronic Myeloid Leukemia(CML)
 
Chronic leukemia
Chronic leukemiaChronic leukemia
Chronic leukemia
 
CML. kamk.pptx
CML. kamk.pptxCML. kamk.pptx
CML. kamk.pptx
 

Kürzlich hochgeladen

Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...raviapr7
 
How to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesHow to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesCeline George
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxAditiChauhan701637
 
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxAUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxiammrhaywood
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxraviapr7
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17Celine George
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfTechSoup
 
The Singapore Teaching Practice document
The Singapore Teaching Practice documentThe Singapore Teaching Practice document
The Singapore Teaching Practice documentXsasf Sfdfasd
 
CAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxCAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxSaurabhParmar42
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...CaraSkikne1
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...Nguyen Thanh Tu Collection
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxMYDA ANGELICA SUAN
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfYu Kanazawa / Osaka University
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxKatherine Villaluna
 
UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024UKCGE
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17Celine George
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapitolTechU
 
How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17Celine George
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxKatherine Villaluna
 

Kürzlich hochgeladen (20)

Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...
 
How to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesHow to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 Sales
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptx
 
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxAUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptx
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
 
The Singapore Teaching Practice document
The Singapore Teaching Practice documentThe Singapore Teaching Practice document
The Singapore Teaching Practice document
 
CAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxCAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptx
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptx
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
 
UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptx
 
How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptx
 
Finals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quizFinals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quiz
 

CML - DIAGNOSIS,MANAGEMENT AND RECENT ADVANCES

  • 1. DIAGNOSIS MANAGEMENT AND RECENT ADVANCES IN CML DR RAJESH S
  • 2. PLAN  Introduction  BCR ABL and its Action  Clinical and Laboratory Features  Goals and Concepts of Management  Diagnostic modalities  Tyrosine Kinase Inhibitors  Other Modalities of treatment  Monitoring Of therapy
  • 3. Chronic Myelogenous Leukemia  CML is a MPD characterized by increased granulocytic cell line, associated with erythroid and platelet hyperplasia.  The diagnosis of CML is established by identifying a clonal expansion of a hematopoietic stem cell possessing a reciprocal translocation between chromosomes 9 and 22.
  • 4. THE BCR-ABL MUTATION  This translocation results in the head-to-tail fusion of the breakpoint cluster region (BCR) gene on chromosome 22q11 with the ABL1 (named after the abelson murine leukemia virus) gene located on chromosome 9q34.
  • 5. The Ph Chromosome: t(9;22) 22 bcr abl Ph ( or 22q-) bcr-abl FUSION PROTEIN WITH TYROSINE KINASE ACTIVITY 9 9 q+
  • 6. Head to tail fusion of BCR to ABL occurs following 9:22 translocation This region is transcribed into BCR-ABL mRNA BCR-ABL protein is produced(p210) This protein Dimerises and becomes active tyrosine kinase Many intracellular kinases are phosphorylated(eg c-myc,shc) Cell proliferates,evades apoptosis
  • 8. Erythrocytes BCR ABL MUTATION OCCURS in MYELOID STEM CELLS ALL COMPONENTS OF MYELOID SERIES i.e MYELOCYTES,RBC’S AND PLATELETS ARE AFFECTED
  • 9. CLINICAL AND LAB FEATURES
  • 10. CLINICAL FEATURES  30% patients are Asymptomatic at diagnosis.  Symptoms are usually Non specific(Fatigue,anorexia,weight loss)  Symptoms because of splenomegaly are common(abdominal pain, dragging sensation in abdomen)  Rare presentations include Vasoocclusive disease, cerebrovascular accidents, myocardial infarction, venous thrombosis, priapism, visual disturbances, and pulmonary insufficiency.
  • 11. LABORATORY FEATURES  Elevated white blood cell counts (WBCs), with increases in both immature and mature granulocytes, are present at diagnosis. Usually <5% circulating blasts and <10% blasts and promyelocytes are noted, with the majority of cells being myelocytes, metamyelocytes, and band forms.  Platelet counts are almost always elevated at diagnosis,  Mild degree of normocytic normochromic anemia is present.  Leukocyte alkaline phosphatase is low in CML cells.
  • 12. LABORATORY FEATURES  The marrow is hypercellular (granulocytic hyperplasia)  Reticulin fibrosis  Hyperuricemia and hyperuricosuria  Serum vitamin B12-binding proteins are increased.  Pseudohyperkalemia, and spurious hypoxemia and hypoglycemia.
  • 14. ACCELERATED PHASE (WHO DEFINITION)  Blasts 10-19% in peripheral blood and or bone marrow.  Peripheral Basophilia ≥20% in peripheral blood.  Persistent thrombocytopenia(<100 x109 )  Persistent thrombocytosis(>1000 x109 )  Increasing spleen size and white blood count despite therapy.  Cytogenetic evidence of clonal evolution 10-19%
  • 15. BLASTIC PHASE (WHO DEFINITION)  Blasts >20% in peripheral blood and or bone marrow.  Extramedullary blast proliferation  Large cluster of Blasts in bone marrow Biopsy. >20%
  • 16. Clinical progression of CML Chronic phase Median 5–6 years stabilization Accelerated phase Median duration 6–9 months Blast crisis Median survival 3–6 months Advanced phases ACQUISITION OF NEW MUTATIONS LIKE TRISOMY 8, P53 MUTATION. BLAST CRISIS IS CONVERSION OF CML INTO AML This acquisition of new mutations is called as CYTOGENIC CLONAL EVOLUTION
  • 17. GOALS, CONCEPTS OF MANAGEMENT AND DIAGNOSTIC MODALITIES
  • 18. Response to treatment can be defined under three sequential categories. 1.Hematological Response 2.Cyto-Genetic Response(CyR) 3.Molecular Response(MR)
  • 19. Definitions of Responses to Treatments Hematologic Response Complete Hematologic response 1) Normal PB counts (WBC < 10 and plt < 450) 2) Normal WBC differential 3) No Dz symptoms 4) Normalization of the size of the liver and spleen Cytogenetic Responses: Ph+ Metaphases 1) complete: 0% 2) partial: 1% - 35% 3) minor: 36% - 65% 4) minimal: 66% - 95% 5) none: 96% - 100% Molecular Responses: ratio of Bcr-Abl/Abl Major Molecular Response 3-log10 reduction from initial diagnosis sample (i.e. 25 →0.025) Amount of Dz 1X1012 1X1011 1X1010 1X10 8-9 CURE???
  • 20. Head to tail fusion of BCR to ABL occurs following 9:22 translocation This region is transcribed into BCR-ABL mRNA BCR-ABL protein is produced(p210) This protein Dimerises and becomes active tyrosine kinase Intracellular kinases are phosphorylated(eg c-myc,shc) Cell proliferates,evades apoptosis Hematological Response is measure by normalization of leukocytes and platelet count and decrease in spleen size Various Guidelines suggest that Complete hematological response should be obtained within 3 months of initiating therapy
  • 21. Complete hematologic response  Complete normalization of PB counts, leukocyte count < 10 x 109/L  Platelet count < 450 x 109/L  No myelocytes, promyelocytes, or blasts in PB  No palpable splenomegaly  No disease symptoms DONE BY : CBC
  • 22. Head to tail fusion of BCR to ABL occurs following 9:22 translocation This region is transcribed into BCR-ABL mRNA BCR-ABL protein is produced(p210) This protein Dimerises and becomes active tyrosine kinase I Intracellular kinases are phosphorylated(eg c-myc,shc) Cell proliferates,evades apoptosis Cyto-genetic response is measured by quantifying 9:22 transolocation. This can be done by 1.Karyotyping/conventional cytogenetics 2.FISH
  • 23. CYTO-GENETIC STUDIES  Requires a bone marrow aspirate for optimal metaphases.  In bone marrow sample, dividing cells are halted at interphase with the help of colchicine and then trypsin and giemsa stains are added in order for G-BANDING of chromosomes.  Allows for evaluation of 9:22 translocation, Clonal evolution as well as additional chromosomal abnormalities in the non-Ph+ clones.  Atleast 20 interphases are examined before reporting.
  • 25. Cytogenetic response  Complete : No Ph+ metaphases  Partial : 1% to 35% Ph+ metaphases  Minor : > 35% Ph+ metaphases  Major : 0% to 35% Ph+ metaphases (complete + partial) Done By: Cyto-genetics/Fish
  • 26. Head to tail fusion of BCR to ABL occurs following 9:22 translocation This region is transcribed into BCR-ABL mRNA BCR-ABL protein is produced(p210) This protein Dimerises and becomes active tyrosine kinase Intracellular kinases are phosphorylated(eg c-myc,shc) Cell proliferates,evades apoptosis Molecular response is measured by quantifying the Bcr-Abl mRNA transcripts. This can be done by 1.QPCR
  • 28. QUANTITATIVE PCR FOR BCR-ABL INTERPRETATION 0 3 6 9 12 15 18 21 24 27 30 33 36 PCR Cycle Number Amount of Fluorescence High Concentration Moderate Concentration Low Concentration
  • 29. Molecular Response  Major Molecular Response(MMR) : ≥ 3 log reduction in BCR-ABL mRNA or BCR-ABL/ABL ≤ 0.1% by QRT-PCR (International Scale)  Complete Molecular Response (CMR) : No detectable BCR-ABL mRNA using assay with sensitivity at least 4.5 logs below standardized baseline Done By: QPCR
  • 30. PROGNOSTIC CLASSIFICATION SOKAL INDEX  Age  Blast percentage  Cytogenic clonal Evolution  Spleen size  Platelet counts HASFORD INDEX  Age  Blast percentage  Basophil and Eosinophils %  Spleen size  Platelet counts
  • 31. TREATMENT WITH TYROSINE KINASE INHIBITORS
  • 34. IMATINIB  Imatinib mesylate (Gleevec) functions through competitive inhibition at the ATP-binding site of the Abl kinase in the inactive conformation, which leads to inhibition of tyrosine phosphorylation of proteins involved in Bcr-Abl signal transduction.  It shows specificity for Bcr-Abl, the receptor for platelet-derived growth factor, and Kit TK.  Imatinib induces apoptosis in cells expressing Bcr-Abl.
  • 35. FAQ ON IMATINIB  What is the dose of imatinib? 400mg / day (maximum dose upto 800 mg can be given)  What is the duration of treatment? At present, treatment should be given for life. Trials in which the drug is stopped after 2 years of achieving CMR has shown promising results.  What are the adverse effects? Myelo-suppression is the most common hematologic side effect. Others are fluid retention, nausea, muscle cramps, diarrhea, and skin rashes.  How to treat myelo-suppression following imatinib therapy? withholding the drug until counts improves. Growth factors like GM-CSF (filgrastim) can be used.
  • 36. FAQ ON IMATINIB  Can we use imatinib in pregnant patients? imatinib is shown to be teratogenic and embryotoxic in animal studies.so it is avoided in pregnancy  Does imatinib affects fertility? It has shown to cause oligospermia. So men desiring conception shold consider sperm cryo-preservation before TKI therapy  When to review the patient for monitoring response? After 3 months of therapy and every 3 months thereafter.
  • 38. MONITORING RESPONSE  Patients on imatinib should be reviewed at 3rd month and investigations to be done at that time are 1.CBC 2.Bone Marrow Cytogenetics/Blood FISH 3.QPCR  If patient had achieved hematological and complete cytological response, then patient can be monitored with QPCR every 3 months thereafter until MMR is aceived, then QPCR can be done every 6 months.  What is the ideal response at 3 months?
  • 39. FAILURE CAN BE BECAUSE OF 1.Resistance to TKI 2.Cytogenic clonal evolution(i.e additional mutations) 3.CML could be Ph negative type 4.Patient adherence problems(missing more than 2 doses in a month)
  • 40. Resistance to imatinib Four mechanisms of resistance to imatinib have been described to date. These are 1. Gene amplification i.e more Bcr-Abl are produced  Treated by increasing dose to 800mg 2. Enhanced expression of multidrug exporter proteins  Treated by increasing dose to 800mg 3. Mutations at the kinase site  Replace with Nilotinib or Dasatinib 4. Alternative signaling pathways functionally compensating for the imatinib - sensitive mechanisms (SRC family of kinases get mutated and they start phosphorylating the kinases)  Replace with Dasatinib
  • 41. KINASE SITE MUTATIONS  Mutations at the kinase domain occur in approximately half of imatinib-resistant chronic-phase cases and even more frequently in the more advanced phases of the disease.  These mutations are being targeted by novel TK inhibitors that have a different conformation than imatinib, demonstrating activity against most imatinib-resistant mutations.  Nilotinib, like imatinib, binds to the kinase domain in the inactive conformation. Dasatinib binds to the kinase domain in the open conformation and also inhibits the SRC (sarcoma) family of kinases, addressing the last mechanism of resistance.  CML with the T315I mutation is resistant to imatinib, nilotinib, and dasatinib
  • 42. Bcr-Abl imatinib Mut. Bcr-Abl imatinib Mut. Bcr-Abl dasatinib
  • 43. NILOTINIB  400 mg twice daily  Associated with sudden death  Causes QT prolongation DASATINIB  100 mg once daily  Causes pleural effusions in 22% of patients.  Causes pulmonary arterial hypertension Both these drugs are now approved also as first line TKI’s for newly diagnosed CML patients by the FDA due to their enhanced Cytogenetic and molecular remissions within short time period
  • 44. NEWER Drugs  Omacetaxine (formerly known as homoharringtonine) Protein translation inhibitor  Sorafenib : Raf kinase inhibitor that down regulates down stream Bcr- Abl targets  FTY720 (also known as fingolimod) : Activation of protein phosphatase 2A that is essential for ABL1-mediated leukemogenesis
  • 45. Allogenic Hematopoietic Stem Cell Transplant(HSCT) INDICATIONS IN CP-CML: 1.Patients with T315I Mutations 2.Bcr-Abl mutations that are resistant to all TKI’s 3.Patient intolerant to TKI’s  Allogenic HSCT is no longer recommended as first line therapy in chronic phase CML. It can be offered to candidates of accelerated or blast crisis.  Even after HSCT TKI’s should be continued till one year.
  • 46. CHEMOTHERAPY  Currently reserved for rapid lowering of WBCs, reduction of symptoms, and reversal of symptomatic splenomegaly.  Hydroxyurea induces rapid disease control. The initial dose is 1–4 g/d; the dose should be halved with each 50% reduction of the leukocyte count. Unfortunately, cytogenetic remissions with hydroxyurea are uncommon.  Busulphan, an alkylating agent that acts on early progenitor cells, has a more prolonged effect. However not used because of its serious side effects, which include unexpected, and occasionally fatal, myelosuppression in 5–10% of patients; pulmonary, endocardial, and marrow fibrosis; and an Addison-like wasting syndrome
  • 47. OTHER MODALITIES  Intensive leukapheresis may control the blood counts in chronic- phase CML; however, it is expensive and cumbersome. It may also have a role in the treatment of pregnant women, in whom it is important to avoid potentially teratogenic drugs.  Splenectomy was used in CML in the past because of the suggestion that evolution to the acute phase might occur in the spleen. However, this does not appear to be the case, and splenectomy is now reserved for symptomatic relief of painful splenomegaly unresponsive to imatinib or chemotherapy, or for significant anemia or thrombocytopenia associated with hypersplenism
  • 48. HOW CAN WE MANAGE CML PATIENTS IN MBGH HOSPITAL SETUP
  • 49. Patients present to us with symptoms and spleenomegaly Patient is suspected of Cml in Peripheral blood film Confirm BCR-ABL with FISH or KARYOTYPING Start on IMATINIB therapy FISH for Bcr-Abl costs Rs.4750 at SRL Religare Diagnostics(4- 7 days) Imatinib starts from Rs.30 per tablet Karyotyping costs Rs.3100 at Amolak Labs and report is available after one month
  • 50. NAME SALT MANUFACTURER COST/DAY PER MONTH 1.RESIMAT IMATINIB RESONANCE LABS RS.30.10 903 2.LUPITIB IMATINIB LUPIN RS.170 5100 3.MITINAB IM.MESYLATE GLENMARK RS.180 5400 4.MESYLONIB IM.MESYLATE MIRACALUS RS.300 9000 5.IMATIB IM.MESYLATE CIPLA RS.300 9000 6.CHEMOTINIB IM.MESYLATE NEON RS.300 9000 7.CELONIB IMATINIB CELON RS.320 9600 8.VEENAT IMATINIB NATCO RS.352 10560

Hinweis der Redaktion

  1. Myeloblast: large nucleus fine chromatin and blue cytoplasmMyelocyte: large nucleus flattened on one side with pink cytoplasmic granulesMetamyelocyte : large nucleus with indented nucleus
  2. 1993: imatinib was patented in us.Europe.at that time no patents in india..so it was produced by generic companies1998: Novartis filed a petition for im.mesylate in india(after india announced that it will allow proxduct patents)2005: indian laws were enacted for product patenting and started processing requestsIndia rejected it saying that just by adding mesylate, it could not patent it for NovartisIt moved to supreme court and final verdict given in apr 2013 that modifications could not be patented.